Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the consistency of quantitative peak stress myocardial blood flow and myocardial blood flow reserve following a 10 second, 1 minute, 2 minute or 4 minute delay in beginning the rubidium-82 infusion post-Lexiscan (regadenoson) injection. It is anticipated that there will be no or minimal difference between the four delay times.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Timothy M. Bateman, MD
• Treatments: Regadenoson

Criteria

Inclusion Criteria:

• Recent normal clinically-indicated exercise myocardial perfusion SPECT, treadmill maximal exercise test or exercise echocardiographic study

• No change in symptoms between the exercise study and PET study

• Capable of providing written informed consent

• BMI 25-32 kg/m2

Exclusion Criteria:

• Diabetes mellitus

• Coronary Artery Calcium Score >25

• Second and Third Degree Atrioventricular Node Block

• Sinus Node Dysfunction

• Recent Syncope of unknown etiology

• Left ventricular hypertrophy per ECG or echocardiography

• Slowed circulation times

• Active wheezing or with acute asthmatic or bronchospastic attacks requiring changes in therapy within the past 30 days.

• Patients that have experienced a previous hypersensitivity reaction thought to be related to Lexiscan